Skip to Content

Fennec Pharmaceuticals Inc FENC

Morningstar Rating
$9.14 +0.14 (1.56%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

FENC is trading at a 1% premium.
Price
$9.15
Fair Value
$5.99
Uncertainty
Very High
1-Star Price
$86.97
5-Star Price
$7.35
Economic Moat
Ncz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FENC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$9.00
Day Range
$8.989.23
52-Week Range
$6.3011.92
Bid/Ask
$3.66 / $12.80
Market Cap
$244.12 Mil
Volume/Avg
88,866 / 130,434

Key Statistics

Price/Earnings (Normalized)
Price/Sales
18.74
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
36

Comparables

Valuation

Metric
FENC
NYKD
EQRX
Price/Earnings (Normalized)
Price/Book Value
3.830.97
Price/Sales
18.7440.74
Price/Cash Flow
Price/Earnings
FENC
NYKD
EQRX

Financial Strength

Metric
FENC
NYKD
EQRX
Quick Ratio
4.336.9518.43
Current Ratio
4.846.9518.78
Interest Coverage
−5.42
Quick Ratio
FENC
NYKD
EQRX

Profitability

Metric
FENC
NYKD
EQRX
Return on Assets (Normalized)
−62.88%−19.18%−15.72%
Return on Equity (Normalized)
−26.31%−16.71%
Return on Invested Capital (Normalized)
−61.22%−30.96%−21.31%
Return on Assets
FENC
NYKD
EQRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGpf$546.8 Bil
VRTX
Vertex Pharmaceuticals IncFktpq$112.0 Bil
REGN
Regeneron Pharmaceuticals IncJthhpgy$108.6 Bil
MRNA
Moderna IncYwgfl$35.9 Bil
ARGX
argenx SE ADRPddh$24.1 Bil
BNTX
BioNTech SE ADRWzrk$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncNrkwpv$20.0 Bil
BMRN
Biomarin Pharmaceutical IncBdfvw$17.0 Bil
RPRX
Royalty Pharma PLC Class AJqqwvt$14.0 Bil
INCY
Incyte CorpFhgbscf$13.6 Bil

Sponsor Center